EXTRACELLULAR MATRIX accumulation/fibrosis is one of the hallmarks of inflammatory diseases in many organ systems, including various chronic renal diseases in humans. Mesangial proliferative glomerulonephritis, the most common type of glomerulonephritis in the Western world (9) , is characterized by mesangial cell (MC) proliferation and extracellular matrix expansion (23) . By up to 50% of the patients with mesangial proliferative glomerulonephritis, the disease process eventually progresses to end-stage renal disease, since specific treatment is still lacking. Typical features of human mesangial proliferative glomerulonephritis are mimicked by an experimental model in the rat, induced by an antibody against the Thy1 antigen on MC (anti-Thy1 model) (23) . The anti-Thy1 model in the rat is characterized by a complement-mediated lysis of the mesangium and invasion of inflammatory cells followed by glomerular fibrosis and repair. Therefore, this model is appropriate to investigate therapeutic effects on inflammation, matrix accumulation, and cellular proliferation.
The matricellular glycoprotein thrombospondin-2 (TSP-2) is a multifunctional protein involved in cell adhesion, migration, proliferation, regulation of matrix metalloproteinases (MMPs), a strong angiogenesis inhibitor, and a competitive inhibitor of thrombospondin-1 (TSP-1)-mediated activation of the transforming growth factor (TGF)-␤ procytokine complex (7, 36) . In our previous work, we examined the role of endogenous TSP-2 during anti-GBM glomerulonephritis by using TSP-2 Ϫ/Ϫ mice (10) . Hereby, TSP-2 Ϫ/Ϫ mice demonstrated an enhanced matrix-remodeling response, increased proliferation of endothelial and tubular cells, as well as an accelerated and enhanced inflammatory response compared with diseased wildtype (wt) mice (10) . Because TSP-2 modulates MMP levels by binding and promotion of endocytosis (40) , we detected increased MMP-2 activity in kidneys from TSP-2 null mice compared with wt mice. In addition, the impact of MMP-2 on renal disease progression has been shown in mice overexpressing MMP-2. At an age of 8 mo, epithelial-mesenchymal transition in renal tubular cells is promoted, and these MMP-2 transgenic mice develop fibrosis, tubular atrophy, glomerular injury, and inflammation (8) .
Therefore, for this study, we hypothesized that therapeutic systemic overexpression of TSP-2 is able to positively influence experimental glomerulonephritis via several different mechanisms such as its antiproliferative and anti-inflammatory properties as well as by antifibrotic effects via competition with TSP-1-mediated TGF-␤ activation and via a reduced MMP-2 activity.
METHODS
Animal model. The animal studies were performed in accordance with the internal animal review board (Regierung von Mittelfranken: 621-2531.31-17/05) and were approved by the national animal review board (Regierung von Mittelfranken: 54 -2532.1-22/08). The animals were housed in a room maintained at 22 Ϯ 2°C, exposed to a 12:12-h dark-light cycle, and fed standard mouse chow (Altromin 1324; Spezialfutterwerke, Lage, Germany) and tap water ad libitum. The experimental design is shown in Fig. 1 . Experimental mesangial proliferative glomerulonephritis (anti-Thy1 model) was induced in 20 male Sprague Dawley rats (180 -200 g; Charles River, Sulzfeld, Germany) by a single injection of 1 mg/kg of the mouse monoclonal anti-Thy1 antibody OX-7 (European Collection of Animal Cell Culture, Salisbury, UK). All rats were randomly allocated to two different groups with anti-Thy1 nephritis receiving either preventive gene therapy with TSP-2 (n ϭ 10) or lacZ as control (n ϭ 10). Renal survival biopsies were taken on days 1 and 3, and rats were killed on day 6. In addition, 14 male anti-Thy1 nephritic Sprague Dawley rats were used in a second experiment using seven rats per TSP-2 and lacZ control group for investigation of glomerular isolates. Glomeruli were isolated by a standard sieving procedure (38) on days 3 and 6 after nephritis induction. For investigation of the phenotype of TSP-2 overexpression in healthy rats, we used six rats each treated either with the TSP-2 or lacZ expression vector. All parameters were additionally investigated in a group of six untreated healthy controls.
Gene therapy. For gene therapy, we used the pCAGGS-lacZ vector (kindly provided by J. Miyazaki and E. Imai, Osaka University Graduate School of Medicine, Osaka, Japan). The lacZ gene was replaced by mouse TSP-2 cut from a pCDNA3.1 derivative (kindly provided by M. Streit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA). Briefly, mTSP-2 was cut from pcDNA3.1 with EcoRI and subsequently ligated into pCAGGS-lacZ digested equally. After induction of the anti-Thy1 model (2 h), left and right thigh muscles were pretreated with 10 units hyaluronidase (30) injected in 100 l sterile PBS. Each thigh muscle received 35 g plasmid DNA containing mouse TSP-2 or lacZ DNA as control. After injection of plasmid DNA (5 min), muscles were transfected by electroporation with six 100-volt pulses of 50-ms duration (each with 950-ms intervals) applied by oval-shaped electrodes using a square wave electroporator (BTX, ECM 830; Genetronix, San Diego, CA) (31) . Successful transfection was verified by immunohistological staining or ␤-galactosidase assay of the thigh muscles and measuring TSP-2 plasma levels by enzyme-linked immunosorbent assay (ELISA) 6 days after plasmid injection.
Renal morphology and immunohistochemistry. Renal biopsies were fixed in methyl Carnoy's solution, embedded in paraffin, and cut into 3-m sections for indirect immunoperoxidase staining as described elsewhere (24) . Sections were also stained with the periodic acidSchiff (PAS) reagent and counterstained with hematoxylin. Paraformaldehyde-fixed biopsies were used for the detection of apoptotic cells by the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling assay (TUNEL) assay. For each biopsy, 40 cortical glomerular cross sections were evaluated in a blinded fashion by two independent observers.
To determine general extracellular matrix formation, sections were also stained with PAS and semiquantitatively scored from zero to four as follows: score 0 ϭ glomerulus without any pink staining, score 1 ϭ glomerulus with little pink staining, score 2 ϭ glomerulus with moderate pink staining, and score 3 ϭ glomerulus almost completely filled with pink staining. Glomerular cell number was determined by counting hematoxylin-stained nuclei per glomerular cross section within a biopsy. Glomerular hypertrophy was determined by measuring the glomerular tuft area of 60 glomerular cross sections with computer-assisted morphometry using Metavue software (Visitron, Puchheim, Germany). All immunohistological evaluations were performed in a blinded fashion by two independent observers.
The following antibodies were used in this study: a murine IgM monoclonal antibody (mAb) against the proliferating cell nuclear antigen (PCNA) (PC10; DAKO, Glostrup, Denmark); ED-1, a murine IgG 1 mAb to a cytoplasmic antigen present in monocytes, macrophages, and dendritic cells [Serotec, Oxford, UK (20) ]; CD3, a rabbit IgG mAb specific for T cells (Labvision, Fremont, CA); CD8a, a murine IgG1 mAb specific for cytotoxic T cells (BD biosciences, Heidelberg, Germany); CD45R, a murine IgG1 mAb specific for B cells (BD biosciences); MHC class II, a murine IgG1 mAb specific for antigen-presenting cells (Serotec); OX-7, a murine IgG1 mAb specific for MCs [Serotec (18) ]; JG-12, a murine IgG mAb specific for rat aminopeptidase P on endothelial cells (25) ; TSP-2, a rabbit polyclonal antibody raised against the NH2-terminal sequence of mouse TSP-2 [kindly provided by P. Bornstein (10) ]; and TSP-1, a murine IgG1 mAb, clone A6.1 specific for TSP-1 [Labvision (12) ]. Immunostaining for matrix proteins was conducted with polyclonal antibodies to collagen I (rabbit anti-rat collagen I; Serotec), collagen IV [goat anti-human/bovine collagen IV; Southern Biotechnology Associates, Birmingham, AL (26)]; and fibronectin (rabbit anti-rat fibronectin; Labvision, Fremont, CA). The TGF-␤ system was studied using antibodies to TGF-␤1 [rabbit anti human TGF-␤1; Santa Cruz Biotechnology, Santa Cruz, CA (12) ]; TGF-␤2 [rabbit anti human TGF-␤2; Santa Cruz (12)]; active TGF-␤1 [chicken anti-human active TGF-␤1 (R&D systems) (12, 13) ], phospho-Smad2/3 [rabbit antihuman Smad2 peptide phosphorylated at Ser 433/435 ; Santa Cruz (12)] or PAI-1, a rabbit polyclonal to human plasminogen activator inhibitor-1 (Santa Cruz), and ␣-smooth muscle actin (1A4), a murine IgG2a mAb to human ␣-smooth muscle actin detecting activated MC from mouse, rat, and human [DAKO (26) ].
Negative controls for immunostaining included either deletion or substitution of the primary antibody with equivalent concentrations of an irrelevant murine mAb or preimmune rabbit IgG. After incubation with primary antibodies overnight at 4°C, specific biotinylated secondary antibodies (all by Vector Laboratories, Burlingame, CA) were applied to tissue sections, followed by peroxidase-conjugated avidin D (Vector), and color development with diaminobenzidine without nickel chloride and histogreen (Linaris, Wertheim-Bettingen, Germany) for nuclear staining.
Glomerular expression of matrix molecules such as collagen IV and fibronectin was quantified by computerized measurement of the positive-stained glomerular area using the Metavue Imaging System (Visitron Systems, Puchheim, Germany) and with equivalent results by a semiquantitative scoring system (data not shown) as described below. Total TGF-␤1, total TGF-␤2, active TGF-␤, collagen I, ␣-smooth muscle actin, TSP-1 and PAI-1 were graded semiquantitatively (18) and reflected changes in the area and intensity of mesangial staining: 0, very weak or absent staining; 1ϩ, weak staining with Ͻ25% of the glomerular tuft showing focally increased staining; 2ϩ, 25-49% of the glomerular tuft with focally increased staining; 3ϩ, 50 -75% of the glomerular tuft demonstrating increased staining; and 4ϩ, Ͼ75% of the glomerular tuft stained strongly. Mesangiolysis was accessed by grading the loss of staining for the MC marker OX-7 semiquantitatively as described above. In addition, the average number of CD3, CD8, myosin heavy chain (MHC) class II, CD45R, ED-1, or PCNA positive cells per glomerular cross section was determined. Phosphorylated Smad2/3 was shown as a percentage of positive nuclei per glomerular cross section counting both positive-and negativestained nuclei.
Immunohistochemical double staining. To determine the number of proliferating mesangial or endothelial cells, double immunostaining for PCNA, a marker of cell proliferation, and for OX-7, a MC specific marker or JG-12, an endothelial specific marker, were performed as described previously (18) . The number of proliferating mesangial and endothelial cells was evaluated by counting the number of cells that stained for both PCNA (green) and OX-7 (brown) or JG-12 (brown) as PCNA ϩ /OX-7 ϩ or PCNA ϩ /JG-12 ϩ cells, respectively, and was expressed as the mean Ϯ SD per glomerular cross section.
Cell culture. Rat MC were cultured from isolated glomeruli using a standard sieving procedure (38) and characterized by positive staining for ␣-smooth muscle actin and ␣ 8-integrin and the lack of the epithelial marker synaptopodin, endothelial marker RECA-1, and the macrophage/monocyte marker CD68. MC were grown in DMEM containing 10% FCS, insulin (5 g/ml), and penicillin/streptomycin at 37°C and 5% CO 2.
Proliferation assay. Proliferation of MCs treated with 0.0001-10 g human TSP-2 (identity of amino acid sequence from predicted rat sequence to human TSP-2 was 88%) (R&D systems) was monitored by Bromodeoxyuridine (BrdU) uptake during S Phase using a cell proliferation ELISA (colorimetric) purchased from Roche Diagnostics (Mannheim, Germany) following the manufacturer's instructions. Two thousand rat MCs were seeded per well of a microtiter plate and starved for 3 days in DMEM culture medium lacking FCS. Pulsing with BrdU was done for 4 h 1 day after stimulation with 5% FCS. Mean proliferative cell activity from three independent experiments was shown by normalizing the positive control to 100%. Apoptosis assay. Apoptotic cells were detected by TUNEL assay, as described previously (10). ␤-Galactosidase assay. Frozen sections from transfected muscles of 10 m thickness were fixed for 10 min in 0.05% glutaraldehyde. After washing in PBS, ␤-galactosidase was detected after incubation for 5 h at 37°C using substrate buffer containing 1 mg/ml x-Gal in 20 mM K 3Fe(CN)6, 20 mM K4Fe(CN)6, and 1.5 mM MgSO4, pH 8.
Zymography. For zymography, proteins from glomeruli were isolated on days 3 and 6 after disease induction and homogenized in 1% (wt/vol) SDS containing 100 mM Tris, pH 6.8. After sedimentation of nonsoluble particles by centrifugation at 14,000 g for 10 min, equal aliquots of 20 g protein were separated at 4°C by 10% SDS-PAGE with 0.06% (wt/vol) gelatin in the resolving gel. SDS was removed by agitation of gels for 120 min in 1% (wt/vol) Triton X-100 in 100 mM Tris, pH 7.5, followed by three subsequent washings for 15 min in 100 mM Tris, pH 7.5. After incubation in the same buffer for 18 h at 37°C, gels were stained with 0.1% (wt/vol) Coomassie brilliant blue R250 in methanol-acidic acid-H 2O (40:10:50) and agitated in the same solution until the stacking gel was destained.
Direct TSP-2 ELISA. Recombinant mouse TSP-2 (kindly provided by P. Bornstein, University of Washington, Seattle, WA) was used for a standard curve using concentrations between 5 and 400 ng/ml. Mouse TSP-2 and an antibody raised against mouse TSP-2 were used to determine total (rat and mouse) TSP-2 serum levels, since there is no rat specific anti-TSP-2 antibody available and identity of amino acid sequence from the predicted rat sequence to mouse TSP-2 is 97%. Recognition of rat TSP-2 by this antibody was proven by Western blot analysis. Standards and plasma samples (1:100) were diluted in PBS and coated on microtiter plates (Nunc immunoplate; Nunc, Roskilde, Denmark) overnight at 4°C, followed by blocking with 1% BSA (Serva, Heidelberg, Germany) and 1% milk powder (Applichem, Darmstadt, Germany) diluted in PBS for 1.5 h. After three rinses with 200 l PBS/well, anti-mouse TSP-2 antibody (kindly provided by P. Bornstein) diluted 1:500 in PBS was incubated for 1 h. After removal of nonbound primary antibody, plates were incubated with horseradish peroxidase-labeled donkey anti-rabbit antibody (GE Healthcare, Little Chalfont Buckinghamshire, UK) diluted 1:200 in PBS. Recognition of bound primary antibody was detected after 1.5 h by addition of peroxidase substrate consisting of 0.4 mg/ml o-phenylenediamine and 0.06% H 2O2 (both Merck, Darmstadt, Germany) in 50 mM phosphate buffer, pH 5. The enzyme reaction was stopped by adding 0.5 M H 2SO4, and the optical density was measured at 492 nm in a microplate reader (Tecan sunrise; Tecan, Salzburg, Austria).
Western blot analysis. The proteins were extracted from isolated glomeruli using 50 mM Tris, 1% (vol/vol) Nonidet P-40, 0.25 (wt/vol) sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM Na 3VO4, 1 mM NaF, and proteinase inhibitor cocktail (Complete; Boehringer, Mannheim, Germany) as extraction buffer. For a better solubility, extracts were sonified for 30 s at 50% power and 50% duty cycle using a Sonoplus HD70 (Bandelin, Berlin, Germany). Twenty micrograms of protein (20 g) were resolved in SDS-PAGE using gels containing 8% acrylamide for analyzing collagen IV (Southern Biotechnology Associates, Birmingham, AL) and fibronectin (Labvision, Fremont, CA). Proteins were transferred semidry to a nitrocellulose membrane within 1 h at 1.5 mA/cm 2 . ␤-Actin (Abcam, Cambridge, UK) was detected simultaneously as a loading control. Secondary peroxidase-conjugated antibodies were all purchased from Amersham Biosciences (Buckinghamshire, UK). For evaluation of densitometry, AIDA 4.1 software (Raytest Isotopenme␤geräte, Straubenhard, Germany) was used. Each experiment for Western blot analysis was done in triplicate.
Quantification of glomerular EDA-fibronectin and collagen I by real-time PCR. The isolation of glomeruli and the quantification of glomerular target proteins by real-time PCR were performed as described (38) .
The following rat-specific PCR primers were used in this study: EDA-fibronectin (38) , forward: 5Ј-ACATCAGTGAATGCCAGTCC-TTT-3Ј, reverse: 5Ј-TCAGAACCGGAACGGAGAAA-3Ј, and probe: 5Ј-TGGTTCAGACTGCAGTGACCAACATTGA-3Ј; collagen IV ␣ 1-chain, forward: 5Ј-AACGAAAGGGACACGAGGA-3Ј; reverse: 5Ј-GGCCAGGAATACCAGGAAGT-3Ј; collagen I ␣1-chain, forward: 5Ј-ATGTTCAGCTTTGTGGACCTC and reverse: 5Ј-GCAGCTGA-CTTCAGGGATGT; 18S (22) , forward: 5Ј-TTGATTAAGTCCCT-GCCCTTTGT-3Ј and reverse: 5Ј-CGATCCGAGGGCCTCACTA-3Ј.
Miscellanous measurements. Urinary protein was measured using the Bio-Rad Protein Assay (Mü nchen, Germany) and BSA (Sigma, Deisenhofen, Germany) as a standard. Creatinine in serum or urine was measured using an autoanalyzer (Beckman Instruments, Mü nchen, Germany).
Statistical analysis. All values are expressed as means Ϯ SE. Statistical significance (defined as P Ͻ 0.05) was evaluated using the Student's t-test or one-way ANOVA with modified t-test using the Bonferroni method.
RESULTS

Endogenous TSP-2 is expressed in nephritic glomeruli on day 6 and was not altered by TSP-2 gene therapy.
In healthy rat kidneys, TSP-2 staining was absent within the glomeruli irrespective of whether muscles were treated with TSP-2-or lacZoverexpressing plasmid (Fig. 2, A and B) . Within the tubulointerstitial compartment, TSP-2 staining was observed in the brush border of some proximal tubules ( Fig. 2A) . Furthermore, TSP-2 overexpression changed neither the renal nor the vascular phenotype of kidneys from healthy rats (data not shown). After disease induction (3 days), glomerular TSP-2 expression was still below detection level (data not shown), but, on day 6, TSP-2 was expressed at low levels within nephritic glomeruli (Fig. 2, C and  D) . This mesangial staining pattern was similar in both treatment groups, indicating that endogenous TSP-2 expression was not influenced by gene therapy (Fig. 2, C and D) .
Overexpression of TSP-2 resulted in TSP-2 production and secretion by muscle cells, causing enhanced TSP-2 plasma levels. Successful transfection of TSP-2-expressing plasmids in the thigh by electroporation could be demonstrated via both immunohistochemical detection of the product in the muscle as well as the detection of increased systemic levels of TSP-2. First, TSP-2 or ␤-galactosidase was detected within the muscle cells using immunohistological staining or ␤-galactosidase assay. TSP-2 was exclusively detected in thigh muscles transfected with TSP-2 overexpression plasmid (Fig. 3A) and not in muscles transfected with the lacZ-expressing plasmid (Fig.  3B) . In addition, ␤-galactosidase activity was restricted to muscle cells transfected with the lacZ-plasmid (Fig. 3, C and Fig. 4 . TSP-2 overexpression decreased glomerular extracellular matrix formation in rats with anti-Thy1 disease. Using periodic acid-Schiff (PAS) staining as an indicator for fibrosis, a marked reduction in pink staining was seen in day 6 glomeruli from the TSP-2-treated group (B) compared with the lacZ control group (A). In addition, immunostaining for collagen IV (D and E, dark gray staining) or fibronectin (G and H, gray staining) was clearly reduced in day 6 glomeruli from the TSP-2-treated animals (E and H) compared with control animals (D and G). Semiquantitative evaluation for PAS positivity (C) and computer-assisted image quantification for collagen IV (F) and fibronectin (I) revealed significant reduced glomerular matrix accumulation in the TSP-2-treated animals. Collagen IV (J) and fibronectin (M) expression on day 6 using isolated glomeruli was investigated by Western blot analysis and analyzed by densitometry (K and N) . Glomerular mRNA expression of collagen I, collagen IV (L), and fibronectin (O) was investigated using real-time PCR. *Statistically significant differences between groups treated with gene therapy (P Ͻ 0.04).
D).
Second, on day 6 after transfection, TSP-2 plasma levels were significantly enhanced and nearly doubled in rats treated with the TSP-overexpressing plasmid compared with animals treated with control plasmid (Fig. 3E) .
Overexpression of TSP-2 did not affect mesangiolysis but ameliorated kidney function. Induction of anti-Thy1 nephritis
was not affected by TSP-2 gene therapy, since mesangiolysis was similar in both groups, as monitored by loss of the rat mesangial marker Thy1 (Fig. 3F) . In contrast, TSP-2 gene therapy in nephritic rats significantly ameliorated kidney function, as measured by creatinine clearance (Fig. 3G) . In addition, 24 h proteinuria, a hallmark of kidney disease severity, was significantly reduced on days 3 and 6 compared with control animals (Fig. 3H) .
TSP-2 overexpression decreased glomerular extracellular matrix formation in rats with anti-Thy1 disease. Amelioration of kidney function was accompanied by reduced glomerular matrix accumulation as evaluated by PAS staining, immunohistochemistry, Western blot analysis, and real-time PCR. In rats treated with the TSP-2-overexpressing plasmid, glomerular PAS positivity was significantly reduced by 52 Ϯ 27% on day 6 after model induction (P Ͻ 0.006; Fig. 4C ) as shown by representative pictures for nephritic glomeruli from rats treated with TSP-2 ( Fig. 4B ) and lacZ gene therapy (Fig. 4A) . Consistent with this result, specific glomerular matrix molecules were significantly reduced in TSP-2-overexpressing animals on day 6 compared with LacZ-expressing controls (Fig. 4) . Accumulation of glomerular collagen IV and fibronectin was reduced in nephritic rats treated with the TSP-2-expressing vector on day 6 after model induction (Fig. 4 , E and H) compared with rats treated with the control vector (Fig. 4 , D and G) as shown in representative images as well as by computer-assisted quantitation of immunostaining (Fig. 4, F  and I ). Western blot analysis and real-time PCR using extracts from isolated glomeruli confirmed collagen IV (Fig. 4, J-L) , collagen I (Fig. 4L) , and fibronectin (Fig. 4, M-O ) reduction in rats treated with TSP-2 gene therapy.
TSP-2 overexpression inhibited MC activation toward a myofibroblast-like phenotype.
In the anti-Thy1 model, repopulating MCs are in an activated state expressing transiently myofibroblast markers such as ␣-smooth muscle actin and collagen I. After induction of anti-Thy1 nephritis (6 days), ␣-smooth muscle actin is homogenously expressed within the regenerating mesangium (Fig. 5A) . In contrast, nephritic glomeruli of TSP-2 gene therapy-treated rats showed only focal ␣-smooth muscle actin expression at the same time point (Fig.  5B) . Glomerular ␣-smooth muscle actin was reduced by Ͼ50% on days 3 and 6 (by semiquantitative scoring) in rats treated with the TSP-2-overexpressing plasmid compared with animals treated with the lacZ control plasmid (Fig. 5C ). Similar results were found for the expression of glomerular collagen I, which was 3.5 times higher on day 6 in the control vectoroverexpressing rats compared with TSP-2-treated animals (Fig.  5, D-F) . MMP-2 is shown to be an inducer for the conversion of cells to the myofibroblast phenotype (8) . Because TSP-2 has been demonstrated as an endogenous regulator of MMP-2, we also investigated MMP-2 activity using zymography. Gene therapy with the TSP-2 construct significantly reduced MMP-2 activity in glomerular extracts from anti-Thy1 nephritic rats on day 3 (Fig. 5, G and H) but was similar on day 6 (Fig. 5, I and J) . Fig. 5 . TSP-2 overexpression reduced mesangial cell activation also by changing glomerular matrix metalloproteinase (MMP)-2 activity. Representative images for immunostaining of ␣-smooth muscle actin showing strong glomerular expression in rats treated with lacZ plasmid (A, dark gray staining) in contrast to low expression within the glomeruli from TSP-2 plasmid-treated animals (B). Semiquantitative evaluation of ␣-smooth muscle actin staining revealed significantly reduced expression in TSP-2 plasmid-treated animals compared with lacZ-control animals. This was also shown for collagen I, as assessed by immunohistochemistry (D). Representative images for immunostaining of collagen I showing strong glomerular expression in rats treated with lacZ-plasmid (E, dark gray staining) in contrast to low expression within the glomeruli from TSP-2 plasmid-treated animals (F). MMP-2 activity was monitored by zymography followed by densitometric evaluation on days 3 (G and H) and 6 (I and J). *Statistically significant differences between groups treated with gene therapy (P Ͻ 0.04).
TSP-2 gene therapy reduced TGF-␤ activation while not affecting total TGF-␤ expression.
If TSP-2 is a competitive inhibitor for TSP-1 in the anti-Thy1 model, TGF-␤ activity in glomeruli from TSP-2-overexpressing plasmid-treated nephritic animals has to be reduced. TSP-1 expression was clearly upregulated during anti-Thy1 nephritis and not significantly different in both treated groups (Fig. 6A) . TGF-␤ activity was monitored using one direct and two different indirect methods. Immunohistochemistry for active TGF-␤ itself, for the phosphorylated form of the TGF-␤ signaling molecule Smad 2/3, and for the TGF-␤ target gene PAI-1 was evaluated. Glomerular staining for active TGF-␤ was significantly reduced by 45 Ϯ 18% on day 3 and 50 Ϯ 21% (P Ͻ 0.0002) on day 6 in nephritic rats treated with TSP-2 gene therapy compared with lacZ-treated controls (Fig. 6B) . Representative images demonstrate that staining for active TGF-␤ (Fig. 6E ) and for PAI-1 (Fig. 6K) was markedly higher in lacZ-treated anti-Thy1 nephritic rats compared with staining in biopsies treated with the TSP-2-overexpressing plasmid (Fig.  6, F and L) . Furthermore, the increase in the percentage of phospho-Smad2/3-positive nuclei per glomerular cross section (Fig. 6C) as well as the increased expression of PAI-1 ( Fig. 6G , P Ͻ 0.002) were more than halved on both investigated time points by TSP-2 gene therapy, indicating reduced TGF-␤ activity. In contrast, total TGF-␤1 and TGF-␤2 were not affected by TSP-2 gene therapy as assessed by immunostaining (Fig. 6, M and N) .
TSP-2 overexpression reduced glomerular proliferation in rats with anti-Thy1 disease. MC proliferation as a hallmark of anti-Thy1 nephritis was also examined in regard to potential effects of TSP-2 gene therapy. Glomerular cell number was similar on day 3 but significantly lower on day 6 in animals treated with the TSP-2-overexpressing plasmid compared with animals treated with the lacZ plasmid (Fig. 7A) . Glomerular proliferation, as assessed by staining for the proliferation marker PCNA, was significantly lower on days 3 and 6 in the TSP-2 gene therapy group (Fig. 7B) . Double staining for the MC marker OX-7 and the proliferation marker PCNA (Fig.  7D) confirmed significantly reduced numbers of proliferating MC on day 6 (27 Ϯ 19% reduction) at the time of its peak proliferation (Fig. 7C) . In contrast, TSP-2-overexpressing nephritic rats exhibited a 50% reduction of the peak glomerular showing a glomerulus from a lacZ-treated rat). TGF-␤ activation was monitored by evaluation of active TGF-␤ (B), showing gray cytosolic staining in biopsies from lacZtreated animals (E). In contrast, staining for active TGF-␤ was much less intensive in rats treated with TSP-2 (F). Evaluation of the phosphorylated (P) TGF-␤ signaling molecule Smad2/3 was conducted by counting the percentage of P-Smad2/3-positive cells per glomerular cross section (C and G, black nuclear phospo-Smad2/3-positive staining). In addition, the TGF-␤ downstream target PAI-1 (H) was highly expressed on day 6 in glomeruli from lacZ-treated rats (K, dark gray cytosolic PAI-1-positive staining) and showed only low expression in glomeruli from rats treated with TSP-2 (L). Total TGF-␤1 (I and M, gray cytosolic TGF-␤1-positive staining in a lacZ-treated rat ) and total TGF-␤2 (J and N, gray cytosolic TGF-␤2-positive staining in a lacZ-treated rat) were similar in both nephritic groups. *Statistically significant differences between groups treated with gene therapy (P Ͻ 0.002).
endothelial cell proliferation (double staining for the endothelial marker JG-12 and PCNA) on day 3 (Fig. 7, E and F) . These results indicate that TSP-2 affects both mesangial and endothelial cell proliferation during anti-Thy1 nephritis.
To investigate TSP-2 effects on glomerular apoptosis, we performed the TUNEL assay. Glomerular apoptosis was neither changed on day 3 nor on day 6 in either group (Fig. 7, G  and H) . Suggesting an direct antiproliferative effect of TSP-2 for MC as similarly demonstrated for glomerular endothelial cells (10) , incubation of isolated rat MCs resulted in significant reduction of the proliferative response (Fig. 7I) . Inhibition of MC proliferation started at concentrations of 0.1 ng/ml TSP-2 and reached a maximum inhibitory effect of 47.6 Ϯ 2.3% when 10 ng/ml were used (Fig. 7I) . In addition, the reduced proliferative response by TSP-2 gene therapy without affecting apoptosis resulted in a significantly reduced glomerular tuft area on days 3 and 6 after disease induction (Fig. 7J) .
Effects of TSP-2 overexpression on kidney inflammation in experimental glomerulonephritis. Because TSP-2 may regulate renal inflammation, we also determined the number of infiltrating T cells, B cells, and monocytes/macrophages within the glomeruli during anti-Thy1 nephritis (Fig. 8) . Highest glomerular infiltration with inflammatory cells was found on day 3 after disease induction (Fig. 8, A, C , E, and G). At this time point, CD3, CD8-positive T cells, and MHCII positive cells were significantly reduced by Ͼ50% using TSP-2 gene therapy (Fig. 8, A, C , and E). On day 6 after model induction, infiltration with T cells and MHCII positive cells was lower compared with day 3 but still significantly reduced by TSP-2 therapy (Fig. 8, A, C, and E) . In contrast, glomerular macrophages and B cells showed only a tendency to reduced levels after treatment with TSP-2 (Fig. 8, G and I) .
DISCUSSION
Mesangial proliferative glomerulonephritis is the most common renal disease in the Western world, leading to fibrosis and end-stage renal disease (23) . In this study, we could show that treatment with TSP-2 by gene therapy was able to ameliorate experimental glomerulonephritis by several different mechanisms, such as inhibition of matrix accumulation, cellular proliferation, and inflammation.
As the first major mechanism, we could demonstrate that TSP-2 can affect TGF-␤ activation, the central cytokine mediating renal fibrosis as indicated by various studies in experimental glomerular disease models as well as human biopsy studies (6, 37) . The fact that the activation process of the TGF-␤ procytokine complex required for its action can be Fig. 7 . TSP-2 overexpression reduced glomerular proliferation in rats with anti-Thy1 disease. Glomerular cell number per glomerular cross section was reduced by TSP-2 gene therapy on day 6 (A). Glomerular cell proliferation, as shown by proliferating cell nuclear antigen (PCNA) staining, was reduced on days 3 and 6 by TSP-2 gene therapy compared with controls treated with lacZ (B). Reduced proliferation was due to significant less mesangial cell proliferation on day 6, as monitored by OX-7-PCNA double staining (C and D, brown cytosolic OX-7-positive mesangium and green nuclear PCNA-positive staining), and less endothelial cell proliferation on day 3, as shown by JG-12-PCNA double staining (E, brown cytosolic JG-12-positive endothelium and F, green nuclear PCNA-positive staining). In contrast, apoptosis, as monitored by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling assay (TUNEL) staining, was not affected in either group (G and H, arrow indicates black nuclear TUNEL-positive staining). The effect of recombinant human (h) TSP-2 on isolated rat mesangial cells was assessed using a bromodeoxyuridine (BrdU) incorporation assay (I). Glomerular tuft area per cross section was significantly reduced in TSP-2 gene therapy-treated animals compared with lacZ-trated controls (J). *Statistically significant differences between groups treated with gene therapy (P Ͻ 0.03). mediated in different ways dependent on its environment (32) could potentially be used for a more specific antagonistic and therapeutic approach (14) . Our group identified TSP-1 as the major endogenous activator of TGF-␤ in experimental mesangial proliferative glomerulonephritis (12, 13) and in diabetic nephropathy (11) . The link of TSP-1 and TGF-␤ in several experimental kidney disease models (1, 12, 13, 17, 19, 25) as well as the de novo upregulation of TSP-1 in human kidney disease (16, 29) suggest TSP-1 as an excellent target for the treatment of renal fibrosis specifically caused by TSP-1-mediated TGF-␤ activation. We believe that TSP-2 overexpression as a therapeutic principle may be advantageous compared with a global TGF-␤ or TSP-1 blocking therapy, since neither alternate TGF-␤ activation mechanisms nor other functions of TSP-1 (for example, as an angiogenesis inhibitor) should be affected (28) . In vitro studies demonstrated that the TSP-1 homologous protein TSP-2 also binds to the latent TGF-␤ complex via its WSHW motif, but lacks the RFK motif, which is essential for TGF-␤ activation (36) . This putative role of TSP-2 as a competitive inhibitor of TSP-1-mediated TGF-␤ activation has not been shown in any in vivo situation (36) .
This proof of concept study demonstrates for the first time that gene therapy using a TSP-2-overexpressing plasmid is feasible and able to inhibit TGF-␤ activation but not expression, as indicated by several different methods, including immunohistochemistry for active or total TGF-␤, the signal transduction complex Smad 2/3, and transcription of TGF-␤ target genes PAI-1 and matrix molecules. These data suggest competition with TSP-1 as the pathophysiological mechanism, since TSP-2 plasma levels were increased, whereas glomerular TSP-1 was unchanged in the TSP-2-overexpressing group. In addition, MC activation and conversion toward the myofibroblast phenotype acquiring de novo expression of ␣-smooth muscle actin and collagen I is considered an important step in renal fibrosis and dependent on TGF-␤ and/or other mediators such as MMPs (8, 39) . TSP-2 overexpression in nephritis inhibited also the mesangial phenotype switch toward a myofibroblast-like type, which also may relate to inhibition of TGF-␤ activation. The beneficial effects as demonstrated in this study are comparable with previous studies antagonizing TGF-␤ by specific antibodies or decorin or TSP-1-blocking peptides or TSP-1 antisense oligonucleotides (12, 13) . Downregulation of MMP-2 is another putative mechanism how TSP-2 can potentially inhibit renal fibrosis. In a recent paper by Cheng et al. (8) , overexpression of MMP-2 in renal tubular cells promoted epithelial-mesenchymal transition and interstitial fibrosis (8) . TSP-2 downregulates MMP-2 activity in vitro by formation of a complex with the zymogen, which inhibits its activation (5), and internalization by an low-density lipoprotein receptor protein 1 with subsequent lysosomal degradation (40) . In our study, glomerular MMP-2 activity was significantly decreased in TSP-2-overexpressing nephritc rats on day 3 but not on day 6, indicating an additional MMP-2-dependent mechanism of myofibroblast conversion in this model (besides regulating TGF-␤ activity). Consistent with this finding, TSP-2 deficiency during experimental glomerulonephritis led to increased MMP-2 activity (10).
The third mechanism how TSP-2 ameliorates anti-Thy1 nephritis is inhibition of glomerular proliferation. In this study, TSP-2 overexpression inhibited both endothelial and mesangial proliferation, leading to reduced excess of glomerular cellularity and size, both of which are important markers of disease. The antiproliferative effect of TSP-2 was shown before, mainly in endothelial cells in vitro (4) and in vivo (10) , while our latter study demonstrated antiproliferative activity also for renal tubular cells. In this study, we could demonstrate a direct antiproliferative effect of TSP-2 on MCs in vitro. This finding most likely relates to direct cell cycle regulatory effects as shown in in vitro studies (4) and seems to be independent of TGF-␤. TGF-␤ inhibits cell proliferation in vitro in different cell types, including MC (35); therefore, reduced TGF-␤ activity should potentially result in excess proliferation. In addition, several in vivo studies either directly blocking TGF-␤ (2, 6) or blocking TSP-1-mediated TGF-␤ activation (12, 13) did not find any change in glomerular proliferative activity during the anti-Thy1 model.
An anti-inflammatory action of TSP-2 is the forth mechanism how TSP-2 can exert beneficial effects during experimental glomerulonephritis. Inflammatory cells can activate MC by secreting a variety of cytokines, including platelet-derived growth factor, tumor necrosis factor-␣, and TGF-␤, resulting in renal fibrosis (15) . Furthermore, chemokines are also known inducers of renal fibrosis (3). For example, inhibition of glomerular leukocyte infiltration by FTY720 slows progression of chronic anti-Thy1 nephritis (34) . In this study, we demonstrated an anti-inflammatory effect of TSP-2 on CD3-, or CD8-positive, T cells as well as MHCII class-positive cells but not on B cells or monocytes/macrophages. In accordance with this finding, TSP-2 deficiency led to an accelerated and increased influx of inflammatory cells during anti-GBM nephritis (10) and in delayed-type hypersensitivity reactions elicited in the skin (27) . TSP-2 seems to exert its anti-inflammatory action by regulation of proinflammatory mediators. In rheumatoid arthritis, TSP-2 suppressed the production of interferon-␥ and tumor necrosis factor-␣ and induced the depletion of tissueresiding T cells (33) . Although no data are available regarding the mechanism by which TSP-2 regulates these mediators, the direct or indirect modulation of the expression or function of chemokines would be consistent with its characteristic features as a matricellular protein (7) .
Because thrombospondins can potentially modulate blood pressure by regulation of nitric oxide signaling (21), we also measured this parameter in our study (data not shown). Blood pressure was neither elevated in the nephritis model on day 6 nor altered by TSP-2 gene therapy, indicating that observed changes were not dependent on changes of blood pressure.
Our study has some limitations. First, in this proof of principle study, because of the short time frame of treatment in our glomerulonephritis model, long-term side effects of TSP-2 overexpression cannot be ruled out. Second, the anti-Thy1 model cannot be directly compared with human mesangial proliferative nephropathy, but does mimic many features of human renal disease, such as TGF-␤ activation, matrix accumulation, myofibroblast conversion, and cellular proliferation.
In conclusion, TSP-2 is a promising therapeutic agent to ameliorate glomerulonephritis by interfering with important pathways of renal disease such as glomerular cell proliferation and activation, influx of inflammatory cells, as well as TGF-␤-and MMP-2-mediated fibrosis.
